Cargando…

M403 COVID-19 IN A PATIENT WITH HYPER-EOSINOPHILIC SYNDROME TREATED WITH MEPOLIZUMAB

Detalles Bibliográficos
Autores principales:	Khakwani, Z., Kumar, S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Published by Elsevier Inc. 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7661915/ http://dx.doi.org/10.1016/j.anai.2020.08.350

Ejemplares similares

Eosinophilic cellulitis (Wells syndrome) successfully treated with mepolizumab
por: Herout, Sandra, et al.
Publicado: (2018)

Severe acute respiratory syndrome coronavirus 2 infection in those on mepolizumab therapy
por: Azim, Adnan, et al.
Publicado: (2021)

Idiopathic hypereosinophilic syndrome with eosinophilic cellulitis-like cutaneous involvement treated with mepolizumab and dapsone
por: Lachance, Madeleine, et al.
Publicado: (2022)

403 International Survey on Evaluation and Management of Eosinophilic Esophagitis
por: Ghaffari, Gisoo
Publicado: (2012)

Blood Eosinophil Depletion with Mepolizumab, Benralizumab, and Prednisolone in Eosinophilic Asthma
por: Moran, Angela M., et al.
Publicado: (2020)

Safety and Efficacy of Mepolizumab in Patients with Eosinophilic Granulomatosis with Polyangiitis
por: Pradhan, Ravi Ranjan, et al.
Publicado: (2019)

Clinical usefulness of mepolizumab in severe eosinophilic asthma
por: Menzella, Francesco, et al.
Publicado: (2016)

A Pediatric Case of Relapsing Eosinophilic Granulomatosis with Polyangiitis Successfully Treated with Mepolizumab
por: Nara, Mizuho, et al.
Publicado: (2019)

Eosinophil‐derived neurotoxin and clinical outcomes with mepolizumab in severe eosinophilic asthma
por: Howarth, Peter, et al.
Publicado: (2020)

Allergic bronchopulmonary aspergillosis complicated by eosinophilic chronic rhinosinusitis successfully treated with mepolizumab
por: Matsumoto, Nobuhiro, et al.
Publicado: (2019)

Patient profiles and clinical utility of mepolizumab in severe eosinophilic asthma
por: Haldar, Pranabashis
Publicado: (2017)

Efficacy of mepolizumab for patients with severe asthma and eosinophilic chronic rhinosinusitis
por: Numata, Takanori, et al.
Publicado: (2019)

Precision medicine in COPD: review of mepolizumab for eosinophilic COPD
por: Long, Gabriella, et al.
Publicado: (2018)

Mepolizumab in the treatment of eosinophilic chronic obstructive pulmonary disease
por: Mkorombindo, Takudzwa, et al.
Publicado: (2019)

Efficacy of add-on mepolizumab in adolescents with severe eosinophilic asthma
por: Yancey, Steven W., et al.
Publicado: (2019)

Effectiveness of mepolizumab for eosinophilic pneumonia following bronchial thermoplasty
por: Otoshi, Ryota, et al.
Publicado: (2019)

Mepolizumab for Eosinophil-Associated COPD: Analysis of METREX and METREO
por: Pavord, Ian D, et al.
Publicado: (2021)

Severe eosinophilic asthma and aspirin-exacerbated respiratory disease associated to eosinophilic gastroenteritis treated with mepolizumab: a case report
por: Caruso, C., et al.
Publicado: (2020)

Effectiveness and safety of mepolizumab in combination with corticosteroids in patients with eosinophilic granulomatosis with polyangiitis
por: Ueno, Masanobu, et al.
Publicado: (2021)

Response to Mepolizumab Treatment in Patients with Severe Eosinophilic Asthma and Atopic Phenotypes
por: Prazma, Charlene M, et al.
Publicado: (2021)

Pharmacogenetic investigation of efficacy response to mepolizumab in eosinophilic granulomatosis with polyangiitis
por: Condreay, Lynn D., et al.
Publicado: (2020)

Mepolizumab therapy improves endomyocarditis in seropositive eosinophilic granulomatosis with polyangiitis
por: Wang, Chrong-Reen, et al.
Publicado: (2022)

Case Report: Mepolizumab in the treatment of idiopathic chronic eosinophilic pneumonia
por: Daboussi, Selsabil, et al.
Publicado: (2023)

Successful treatment with benralizumab in a patient with eosinophilic granulomatosis with polyangiitis refractory to mepolizumab
por: Menzella, Francesco, et al.
Publicado: (2021)

Fungal sensitization and its relationship to mepolizumab response in patients with severe eosinophilic asthma
por: Wardlaw, Andrew, et al.
Publicado: (2020)

Low-Dose Mepolizumab Effectiveness in Patients Suffering From Eosinophilic Granulomatosis With Polyangiitis
por: Vultaggio, Alessandra, et al.
Publicado: (2020)

Use of mepolizumab in adult patients with cystic fibrosis and an eosinophilic phenotype: case series
por: Zhang, Lijia, et al.
Publicado: (2020)

Treatment response with mepolizumab in severe eosinophilic asthma patients with previous omalizumab treatment
por: Magnan, A., et al.
Publicado: (2016)

Update: Mepolizumab treatment in patients with severe eosinophilic asthma and prior omalizumab use
por: Albers, Frank C., et al.
Publicado: (2019)

Dysphonia and dyspnea in idiopathic hypereosinophilic syndrome treated with Mepolizumab
por: Kay, Dana, et al.
Publicado: (2018)

Evaluation of sputum eosinophil count as a predictor of treatment response to mepolizumab
por: Pavord, Ian D., et al.
Publicado: (2022)

Mepolizumab for Eosinophilic Granulomatosis With Polyangiitis: A European Multicenter Observational Study
por: Bettiol, Alessandra, et al.
Publicado: (2021)

Successful Treatment With Mepolizumab for Eosinophilic Granulomatosis With Polyangiitis: A Case Report
por: Toscano Peña, Andrés, et al.
Publicado: (2023)

Concurrent Use of Mepolizumab and Rituximab for Eosinophilic Granulomatosis With Polyangiitis and Multisystem Involvement
por: Afiari, Agura, et al.
Publicado: (2020)

Mepolizumab: an alternative therapy for idiopathic chronic eosinophilic pneumonia with glucocorticoid intolerance
por: Kisling, Adam, et al.
Publicado: (2020)

The clinical benefit of mepolizumab replacing omalizumab in uncontrolled severe eosinophilic asthma
por: Chapman, Kenneth R., et al.
Publicado: (2019)

Economic impact of mepolizumab in uncontrolled severe eosinophilic asthma, in real life()
por: Bagnasco, Diego, et al.
Publicado: (2021)

Renal Involvement as Rare Acute Tubulointerstitial Nephritis in a Patient with Eosinophilic Disorder Treated with Early Add-on Administration of Mepolizumab
por: Hayama, Yuto, et al.
Publicado: (2021)

Differential effects of short- and long-term treatment with mepolizumab on eosinophil kinetics in blood and sputum in eosinophilic asthma
por: Hassani, Marwan, et al.
Publicado: (2021)

Real-world characteristics of “super-responders” to mepolizumab and benralizumab in severe eosinophilic asthma and eosinophilic granulomatosis with polyangiitis
por: Portacci, Andrea, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_1g7hoht492u1sfl5rm8g7iv4eo